PlainRecalls
FDA Drug Low Class III Terminated

buPROPion HCl Extended-Release Tablets, USP (SR), 150 mg ,a) 60 count (NDC 69097-878-03) and b) 100 count (NDC 69097-878-07) bottles, Rx Only, Manufactured for: Cipla USA Inc. 1560 Sawgrass Corporate Parkway Suite 130 Sunrise, FL 33323, Manufactured by: InvaGen Pharmaceuticals, Inc. (a subsidiary of Cipla Ltd.) Hauppauge, NY 11788

Reported: April 11, 2018 Initiated: March 15, 2018 #D-0619-2018

Product Description

buPROPion HCl Extended-Release Tablets, USP (SR), 150 mg ,a) 60 count (NDC 69097-878-03) and b) 100 count (NDC 69097-878-07) bottles, Rx Only, Manufactured for: Cipla USA Inc. 1560 Sawgrass Corporate Parkway Suite 130 Sunrise, FL 33323, Manufactured by: InvaGen Pharmaceuticals, Inc. (a subsidiary of Cipla Ltd.) Hauppauge, NY 11788

Reason for Recall

Failed Dissolution Specifications; during stability testing

Details

Units Affected
N/A
Distribution
Nationwide
Location
Hauppauge, NY

Frequently Asked Questions

What product was recalled?
buPROPion HCl Extended-Release Tablets, USP (SR), 150 mg ,a) 60 count (NDC 69097-878-03) and b) 100 count (NDC 69097-878-07) bottles, Rx Only, Manufactured for: Cipla USA Inc. 1560 Sawgrass Corporate Parkway Suite 130 Sunrise, FL 33323, Manufactured by: InvaGen Pharmaceuticals, Inc. (a subsidiary of Cipla Ltd.) Hauppauge, NY 11788. Recalled by InvaGen Pharmaceuticals, Inc.. Units affected: N/A.
Why was this product recalled?
Failed Dissolution Specifications; during stability testing
Which agency issued this recall?
This recall was issued by the FDA Drug on April 11, 2018. Severity: Low. Recall number: D-0619-2018.